SLC5A2 and chronic kidney disease: Sodium–glucose cotransporter 2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, are a well-established pharmacological class for renoprotection in CKD, with their benefits in slowing renal decline widely recognized [198,199].